ReviewNature nanotechnology2024
Designing nanotheranostics with machine learning.
Review in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: a systematic review and meta-analysis.Ultrasonics sonochemistry · 2026Pooled it
- Hit the bull's eye: Engineered extracellular vesicles for targeted therapy.Bioactive materials · 2026Review
- Advanced Nanomaterials for Biological, Medical, and Environmental Applications: Current Progress and Future Perspectives.Materials (Basel, Switzerland) · 2026Article
- 900°C thermal-force coupling carbonization tailoring hard carbon microstructures enables high performance sodium-ion pouch batteries.Nature communications · 2026Article
- Advances and Clinical Translation Potentials of Functional Nanomaterials in Tissue Engineering.Bioengineering (Basel, Switzerland) · 2026Review
- Bio-orthogonal Chemistry-Facilitated Zn-Mn Double-Layered Nanobombs Abrogate cGAS-STING Evasion of Tumor Cells.Advanced healthcare materials · 2026Article
- Spatiotemporal immunomodulation with programmable biomaterials to promote musculoskeletal tissue regeneration.Bioactive materials · 2026Review
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
- Nanozymes for ferroptosis-based cancer theranostics.Bioactive materials · 2026Review
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics.Chemical Society reviews · 2026Review
- Illuminating the metabolic sink: Optical probes for in vivo thermogenic fat imaging.Materials today. Bio · 2026Review
- Polymer Nanoparticles in Medical Applications-Future Directions.Nanomaterials (Basel, Switzerland) · 2026Review
- Immunoregulatory protein-hybrid extracellular vesicles via self-loadable backbone cyclization for oral inflammatory bowel disease therapy.Bioactive materials · 2026Article
- Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Artificial intelligence-driven nano-enhanced stem cell therapy for neurodegenerative diseases: from rational design to clinical translation.Journal of nanobiotechnology · 2026Review
- Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery.Acta pharmaceutica Sinica. B · 2026Review
- Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery.Biomaterials · 2026Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The inherent limits of traditional diagnoses and therapies have driven the development and application of emerging nanotechnologies for more effective and safer management of diseases, herein referred to as 'nanotheranostics'. Although many important technological successes have been achieved in this field, widespread adoption of nanotheranostics as a new paradigm is hindered by specific obstacles, including time-consuming synthesis of nanoparticles, incomplete understanding of nano-bio interactions, and challenges regarding chemistry, manufacturing and the controls required for clinical translation and commercialization. As a key branch of artificial intelligence, machine learning (ML) provides a set of tools capable of performing time-consuming and result-perception tasks, thus offering unique opportunities for nanotheranostics. This Review summarizes the progress and challenges in this emerging field of ML-aided nanotheranostics, and discusses the opportunities in developing next-generation nanotheranostics with reliable datasets and advanced ML models to offer better clinical benefits to patients.
Indexed as
Identifiers
39362960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.